NOVEL CANNABIDIOL QUINONE DERIVATIVES

    公开(公告)号:EP3131874B1

    公开(公告)日:2018-07-25

    申请号:EP14723345.6

    申请日:2014-04-16

    IPC分类号: C07C69/75 C07C225/28

    摘要: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamineor alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I)as medicamentsin therapy, particularly for treating diseasesand conditions responsive to PPARg modulationdue to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

    NOVEL CANNABIDIOL QUINONE DERIVATIVES
    5.
    发明公开
    NOVEL CANNABIDIOL QUINONE DERIVATIVES 有权
    中性抗坏血酸 - 中文衍生物

    公开(公告)号:EP3131874A1

    公开(公告)日:2017-02-22

    申请号:EP14723345.6

    申请日:2014-04-16

    IPC分类号: C07C69/75 C07C225/28

    摘要: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamineor alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I)as medicamentsin therapy, particularly for treating diseasesand conditions responsive to PPARg modulationdue to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

    摘要翻译: 本发明涉及式(I)(I)的新型大二酚醌衍生物,其中R是直链或支链基团的碳原子,由烷基,芳基,烯基,炔基,酰基或烷氧基羰基表示; 或其中R为直链或支链基团的氮原子,由:烷基胺,芳基胺,链烯基胺或炔基胺基团表示。 本发明还涉及任何式(I)化合物作为治疗药物的用途,特别是用于治疗对PPARg调节有反应的疾病和病症,这是由于它们的高PPARg激动作用缺乏亲电子(Nrf2活化)和细胞毒活性。 本发明还提供包含所述化合物的药物组合物和用所述化合物治疗疾病的方法。

    Novel cannabigerol derivatives
    6.
    发明公开
    Novel cannabigerol derivatives 审中-公开
    新型cannabigerol衍生物

    公开(公告)号:EP2913321A1

    公开(公告)日:2015-09-02

    申请号:EP14156954.1

    申请日:2014-02-27

    摘要: The present invention relates to novel cannabigerol quinone derivatives of formula (I)

    wherein R is the carbon atom of a linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl, or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

    摘要翻译: 本发明涉及式(I)的新型大麻素醌衍生物,其中R为直链或支链基团的碳原子,由以下各项表示:烷基,芳基,烯基,炔基,酰基或烷氧基碳酰基; 或其中R是直链或支链基团的氮原子,由以下基团表示:烷基氨基,芳基氨基,烯基氨基或炔基氨基; 或者,或者,R代表形成二聚体的2个式(I)分子之间的键。 本发明还涉及式(I)的任何化合物作为药物在治疗中的应用,特别是用于治疗PPARg相关疾病,因为它们具有缺乏亲电子(Nrf2激活)和细胞毒性活性的高PPARg激动作用。 本发明还提供了包含所述化合物的药物组合物和用所述化合物治疗疾病的方法。